Company Overview and News

 
KLCI sees limited gains ahead of BNM monetary policy meet tomorrow

2016-11-22 theedgemarkets
KUALA LUMPUR (Nov 22): The FBM KLCI saw limited gains at the midday break today as decliners overtook advancers ahead of Bank Negara Malaysia's monetary policy meeting tomorrow.

 
KLCI pares gains, but remains positive as crude oil price rises

2016-11-22 theedgemarkets
KUALA LUMPUR (Nov 22): The FBM KLCI pared some its gains at mid-morning today in line with the firmer regional markets and rise in crude oil prices.

 
KLCI pares gains in line with nervy regional markets

2016-09-20 theedgemarkets
KUALA LUMPUR (Sept 20): The FBM KLCI pared some of its gains at mid-morning today, in line with the nervy regional markets.

 
Focus Lumber gains 1.95% on positive outlook

2016-09-20 theedgemarkets
KUALA LUMPUR (Sept 20): Focus Lumber Bhd (FLBhd) shares rose 1.95% in early trade today after Hong Leong IB Research said FLBhd was bottoming up and that FLBhd is expected to play catch up against its peers as momentum built up yesterday following a 3.35% gain in share price and nearly 2.7 million shares (100% and 137% higher against 1M/3M average) changing hand.

 
KLCI edges up marginally but gains seen capped

2016-09-20 theedgemarkets
KUALA LUMPUR (Sept 20): The FBM KLCI edged up in early trade today, lifted by select blue chips but gains were seen limited in line with the cautious regional markets.

 
KLCI at intraday high on bargain hunting

2016-05-23 theedgemarkets
KUALA LUMPUR (May 23): The FBM KLCI gained 6.1 points or 0.4% as investors bargain hunted for Malaysian stocks following earlier intraday losses.

 
KLCI inches up in line with regional gains

2016-05-23 theedgemarkets
KUALA LUMPUR (May 23): The FBM KLCI inched up at the midday break, in line with regional gains.

 
KLCI dips, select blue chips, Petronas linked stocks weigh

2016-05-23 theedgemarkets
KUALA LUMPUR (May 23): The FBM KLCI dipped at morning today, weighed by select blue chips, including Petronas-linked counters.

 
Breakfast briefing: Monday, May 16

2016-05-16 thestar.com.my
MarketWatch: As the anniversary of the S&P 500's high mark approaches, the benchmark US stock index's latest rally has stalled and failed to breach a key level, prompting some calls for sell-offs, at least in the short term. - Reuters Top foreign stories Google faces record 3 billion euro EU antitrust fine: Google faces a record antitrust fine of around 3 billion euros (US$3.4 billion) from the European Commission in the coming weeks, The Sunday Telegraph reported.

 
Koon tells his side of story

2016-05-15 thestar.com.my
Lower volume: Koon may restrict his buying of stocks to less than 5 so that it would need no disclosures.

 
Koon not the only one

2016-05-14 thestar.com.my
HIGH profile investor Koon Yew Yin has been creating headlines for all the wrong reasons recently.

 
KLCI slumps 0.94% as regional markets back-pedal, key stocks weigh

2016-05-13 theedgemarkets
KUALA LUMPUR (May 13): The FBM KLCI slumped 0.94% at mid-morning today as regional markets bak-pedalled and key blue chips weighed.

 
KLCI notches up marginal gains

2016-05-12 theedgemarkets
KUALA LUMPUR (May 12): The FBM KLCI notched up marginal gains at the midday break today, reversing its earlier losses, lifted by select blue chips.

 
KLCI loses 0.79% in line with regional slump

2016-04-18 theedgemarkets
KUALA LUMPUR (April 18): The FBM KLCI lost 0.79% at the midday break today in line with the slump at most regional markets as crude oil prices tumbled.

 
KLCI slips below 1,720 on regional weakness

2016-04-18 theedgemarkets
KUALA LUMPUR (April 18): The FBM KLCI slipped below the 1,720 point level at mid-morning today in line with the dip at most regional markets.

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

22h - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

23h - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...